Akkermansia Muciniphilia and Metabolic Side Effects of ADT
Recruiting now · Early Phase 1
Conditions studied: Prostate Cancer, Metabolic Syndrome, Obesity, Cardiovascular Morbidity, Bone Diseases, Hyperlipidemias, Diabetes
In brief
The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm. 2. To confirm tolerability and assess for side effects of oral acetate supplementation. 2. Secondary outcomes: 1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.
Key facts
- Study ID
- NCT05802121
- Run by
- Western University
- People needed
- 30
- Starts
- 2025-07-02
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2025-08-20
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- London Health Sciences Centre - Victoria Hospital — London, Ontario, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.